orforglipron   Click here for help

GtoPdb Ligand ID: 12175

Synonyms: LY-3502970 | LY3502970 | OWL833
PDB Ligand
Compound class: Synthetic organic
Comment: Oforglipron (LY3502970) is an oral, nonpeptide glucagon-like peptide-1 receptor (GLP-1R) agonist that was developed as a potential antidiabetic medication [1-3]. It is a partial agonist (relative to native GLP-1), that biases GLP-1R signalling towards G protein activation and is devoid of β-arrestin recruitment activity.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

orforglipron is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 154.37
Molecular weight 882.38
XLogP 7.77
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES O=c1onc([nH]1)[C@@]1(C[C@@H]1C)n1c(cc2c1ccc(c2)[C@H]1CCOC(C1)(C)C)C(=O)N1CCc2c([C@@H]1C)c(n(n2)c1cc(C)c(c(c1)C)F)n1ccn(c1=O)c1ccc2c(c1F)cnn2C
Isomeric SMILES C[C@H]1C[C@]1(c1noc(=O)[nH]1)n1c2c(cc(cc2)[C@H]2CCOC(C2)(C)C)cc1C(=O)N1CCc2nn(c(c2[C@@H]1C)n1ccn(c1=O)c1c(c2c(cc1)n(nc2)C)F)c1cc(c(c(c1)C)F)C
InChI InChI=1S/C48H48F2N10O5/c1-25-18-32(19-26(2)40(25)49)60-42(58-16-15-57(46(58)63)37-11-10-36-33(41(37)50)24-51-55(36)7)39-28(4)56(14-12-34(39)53-60)43(61)38-21-31-20-29(30-13-17-64-47(5,6)23-30)8-9-35(31)59(38)48(22-27(48)3)44-52-45(62)65-54-44/h8-11,15-16,18-21,24,27-28,30H,12-14,17,22-23H2,1-7H3,(H,52,54,62)/t27-,28-,30-,48-/m0/s1
InChI Key USUWIEBBBWHKNI-KHIFEHGGSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
LY3502970 is in clinical development as a treatment for obesity and type 2 diabetes mellitus.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05086445 A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus Phase 1 Interventional Eli Lilly and Company
NCT05048719 A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus Phase 2 Interventional Eli Lilly and Company
NCT05313802 A Study of LY3502970 in Healthy Overweight and Obese Participants Phase 1 Interventional Eli Lilly and Company
NCT04426474 A Study of LY3502970 in Participants With Type 2 Diabetes Phase 1 Interventional Eli Lilly and Company 4
NCT05051579 A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2 Interventional Eli Lilly and Company 6
NCT06010004 A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3 Interventional Eli Lilly and Company
NCT05869903 A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities Phase 3 Interventional Eli Lilly and Company
NCT03929744 A Study of LY3502970 in Healthy Participants Phase 1 Interventional Eli Lilly and Company 4-5